RESUMO
BACKGROUND: An estimated 60% of pharmacological randomised trials use placebo control interventions to blind (i.e. mask) participants. However, standard placebos do not control for perceptible non-therapeutic effects (i.e. side effects) of the experimental drug, which may unblind participants. Trials rarely use active placebo controls, which contain pharmacological compounds designed to mimic the non-therapeutic experimental drug effects in order to reduce the risk of unblinding. A relevant improvement in the estimated effects of active placebo compared with standard placebo would imply that trials with standard placebo may overestimate experimental drug effects. OBJECTIVES: We aimed to estimate the difference in drug effects when an experimental drug is compared with an active placebo versus a standard placebo control intervention, and to explore causes for heterogeneity. In the context of a randomised trial, this difference in drug effects can be estimated by directly comparing the effect difference between the active placebo and standard placebo intervention. SEARCH METHODS: We searched PubMed, CENTRAL, Embase, two other databases, and two trial registries up to October 2020. We also searched reference lists and citations and contacted trial authors. SELECTION CRITERIA: We included randomised trials that compared an active placebo versus a standard placebo intervention. We considered trials both with and without a matching experimental drug arm. DATA COLLECTION AND ANALYSIS: We extracted data, assessed risk of bias, scored active placebos for adequacy and risk of unintended therapeutic effect, and categorised active placebos as unpleasant, neutral, or pleasant. We requested individual participant data from the authors of four cross-over trials published after 1990 and one unpublished trial registered after 1990. Our primary inverse-variance, random-effects meta-analysis used standardised mean differences (SMDs) of active versus standard placebo for participant-reported outcomes at earliest post-treatment assessment. A negative SMD favoured the active placebo. We stratified analyses by trial type (clinical or preclinical) and supplemented with sensitivity and subgroup analyses and meta-regression. In secondary analyses, we investigated observer-reported outcomes, harms, attrition, and co-intervention outcomes. MAIN RESULTS: We included 21 trials (1462 participants). We obtained individual participant data from four trials. Our primary analysis of participant-reported outcomes at earliest post-treatment assessment resulted in a pooled SMD of -0.08 (95% confidence interval (CI) -0.20 to 0.04; I2 = 31%; 14 trials), with no clear difference between clinical and preclinical trials. Individual participant data contributed 43% of the weight of this analysis. Two of seven sensitivity analyses found more pronounced and statistically significant differences; for example, in the five trials with low overall risk of bias, the pooled SMD was -0.24 (95% CI -0.34 to -0.13). The pooled SMD of observer-reported outcomes was similar to the primary analysis. The pooled odds ratio (OR) for harms was 3.08 (95% CI 1.56 to 6.07), and for attrition, 1.22 (95% CI 0.74 to 2.03). Co-intervention data were limited. Meta-regression found no statistically significant association with adequacy of the active placebo or risk of unintended therapeutic effect. AUTHORS' CONCLUSIONS: We did not find a statistically significant difference between active and standard placebo control interventions in our primary analysis, but the result was imprecise and the CI compatible with a difference ranging from important to irrelevant. Furthermore, the result was not robust, because two sensitivity analyses produced a more pronounced and statistically significant difference. We suggest that trialists and users of information from trials carefully consider the type of placebo control intervention in trials with high risk of unblinding, such as those with pronounced non-therapeutic effects and participant-reported outcomes.
Assuntos
Suplementos Nutricionais , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Emoções , Razão de Chances , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
BACKGROUND: The efficacy of fusion surgery in addition to decompression surgery in patients who have lumbar spinal stenosis, with or without degenerative spondylolisthesis, has not been substantiated in controlled trials. METHODS: We randomly assigned 247 patients between 50 and 80 years of age who had lumbar spinal stenosis at one or two adjacent vertebral levels to undergo either decompression surgery plus fusion surgery (fusion group) or decompression surgery alone (decompression-alone group). Randomization was stratified according to the presence of preoperative degenerative spondylolisthesis (in 135 patients) or its absence. Outcomes were assessed with the use of patient-reported outcome measures, a 6-minute walk test, and a health economic evaluation. The primary outcome was the score on the Oswestry Disability Index (ODI; which ranges from 0 to 100, with higher scores indicating more severe disability) 2 years after surgery. The primary analysis, which was a per-protocol analysis, did not include the 14 patients who did not receive the assigned treatment and the 5 who were lost to follow-up. RESULTS: There was no significant difference between the groups in the mean score on the ODI at 2 years (27 in the fusion group and 24 in the decompression-alone group, P=0.24) or in the results of the 6-minute walk test (397 m in the fusion group and 405 m in the decompression-alone group, P=0.72). Results were similar between patients with and those without spondylolisthesis. Among the patients who had 5 years of follow-up and were eligible for inclusion in the 5-year analysis, there were no significant differences between the groups in clinical outcomes at 5 years. The mean length of hospitalization was 7.4 days in the fusion group and 4.1 days in the decompression-alone group (P<0.001). Operating time was longer, the amount of bleeding was greater, and surgical costs were higher in the fusion group than in the decompression-alone group. During a mean follow-up of 6.5 years, additional lumbar spine surgery was performed in 22% of the patients in the fusion group and in 21% of those in the decompression-alone group. CONCLUSIONS: Among patients with lumbar spinal stenosis, with or without degenerative spondylolisthesis, decompression surgery plus fusion surgery did not result in better clinical outcomes at 2 years and 5 years than did decompression surgery alone. (Funded by an Uppsala institutional Avtal om Läkarutbildning och Forskning [Agreement concerning Cooperation on Medical Education and Research] and others; Swedish Spinal Stenosis Study ClinicalTrials.gov number, NCT01994512.).
Assuntos
Descompressão Cirúrgica , Vértebras Lombares/cirurgia , Fusão Vertebral , Estenose Espinal/cirurgia , Idoso , Avaliação da Deficiência , Feminino , Seguimentos , Humanos , Análise de Intenção de Tratamento , Vértebras Lombares/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Radiografia , Reoperação/estatística & dados numéricos , Estenose Espinal/complicações , Espondilolistese/complicações , Espondilolistese/cirurgia , Resultado do TratamentoRESUMO
OBJECTIVE: To identify, characterize, and explore author guides on the role, format, and content of protocols for observational epidemiological studies, particularly cohort and case-control studies. STUDY DESIGN AND SETTING: Scoping review. We searched for guides in Medline, Embase, Google Scholar, 10 general medical and epidemiological/public health journals, and 10 major funders' websites. Two review authors extracted data. We classified guides as "main" based on word count and number of protocol items, described such guides more comprehensively and analyzed number of citations as an indicator of uptake. RESULTS: Thirty-nine protocol guides were included intended for cohort studies (n = 3), case-control studies (n = 1), or epidemiological studies in general (n = 35). Content and format were highly variable. Several guides had a broader focus than protocol development, e.g., also including study conduct and reporting. The guideline developmental process was often reported sparsely. One guide, intended for interventional studies, combined a systematic preparatory process with a primary focus on protocol development. We categorized seven guides as 'main'. In general the guides were cited infrequently, indicating limited uptake. CONCLUSION: Guides for authors of protocols for observational epidemiological studies varied highly in format and content. We suggest that such guides should routinely be based on a systematic preparatory process.
Assuntos
Projetos de Pesquisa , Humanos , Estudos de Coortes , Estudos de Casos e Controles , MEDLINERESUMO
STUDY DESIGN: Cohort study. OBJECTIVE: To study the clinical outcome, complications and subsequent surgery rate of DA for lumbar spinal stenosis (LSS) with DS. SUMMARY OF BACKGROUND DATA: There is still no consensus regarding the treatment approach for LSS with DS. METHODS: We performed a retrospectively designed cohort study on prospectively collected data from a single high productive spine surgical center. Results from the Swedish Spine Registry and a local register for complications were used for the analyses. Patients with LSS and DS (>3âmm) who underwent DA during January 2012 to August 2017 were included. Patient reported outcome measures at baseline and 2 years after surgery were analyzed. Complications within 30âdays of surgery and all subsequent surgery in the lumbar spine were registered. RESULTS: We identified and included 346 patients with completed 2-year follow-up registration. At 2-year follow-up there was a significant improvement in all outcome measures. The global assessment success rate for back and leg pain was 68.3% and 67.6% respectively. Forty-one patients had at least 1 intra- or postoperative complication (11.9%). Nine patients (2.6%), underwent subsequent surgery within 2 years of the primary surgery whereof 2 underwent fusion. During the whole period of data collection, that is, as of June 2020, 28 patients had undergone subsequent surgery (8.1%) whereas 8 of them had had 2 surgeries. Fifteen patients underwent fusion. CONCLUSION: DA provides good clinical outcome at 2-year follow-up in patients with LSS and DS with low rate of intra- and postoperative complications and subsequent surgery. Our data supports the evidence that DA is effective and safe for LSS with DS.Level of Evidence: 3.
Assuntos
Fusão Vertebral , Estenose Espinal , Espondilolistese , Estudos de Coortes , Descompressão Cirúrgica/efeitos adversos , Descompressão Cirúrgica/métodos , Humanos , Vértebras Lombares/cirurgia , Estudos Retrospectivos , Fusão Vertebral/efeitos adversos , Fusão Vertebral/métodos , Estenose Espinal/complicações , Espondilolistese/complicações , Resultado do TratamentoRESUMO
OBJECTIVES: The objective of the study was to investigate to which degree systematic review protocols adhere to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) reporting guideline. STUDY DESIGN AND SETTING: We randomly sampled 50 publications of systematic review protocols indexed in PubMed and 50 protocols uploaded to the International Prospective Register of Systematic Reviews (PROSPERO) from 2016 onward. Two authors independently extracted data and assessed adherence to the 26 items specified by PRISMA-P. For each protocol, we categorized adherence to PRISMA-P as complete (≥90% of PRISMA-P items were fully reported) or partial (≥60% of PRISMA-P items were fully reported). We also assessed adherence to each PRISMA-P item across the protocols. RESULTS: Four (8%) of the PubMed-indexed protocols adhered completely and 45 (90%) adhered partially to PRISMA-P but with considerable variation. None (0%) of the PROSPERO-uploaded protocols adhered completely and only 6 (12%) adhered partially to PRISMA-P. For both types of protocols, aspects related to the role of the sponsor, procedures for doing qualitative data synthesis if quantitative synthesis is not appropriate, and methods for assessing publication or outcome reporting biases and confidence in cumulative evidence were often not reported. CONCLUSION: Adherence to the PRISMA-P reporting guideline was somewhat inadequate in PubMed-indexed protocols and clearly inadequate in PROSPERO-uploaded protocols. Authors of systematic review protocols who decide to report according to PRISMA-P should carefully check all items included in the guideline, and journal editors and peer reviewers should consider PRISMA-P adherence when reviewing protocols for potential publication.
Assuntos
Revisões Sistemáticas como Assunto , Humanos , Viés , Confiabilidade dos Dados , Fidelidade a Diretrizes , Projetos de PesquisaRESUMO
Cytokines regulate proliferation, differentiation and activation of osteoblasts. Interleukin-4 (IL-4) and interleukin-13 (IL-13) takes part in this regulation by inhibiting proliferation and by enhancement of interleukin-6 (IL-6) formation in cultured human osteoblasts (hOBs). In the present study we have investigated the effects of IL-4 and IL-13 on markers of osteoblastic activity in isolated hOBs. Treatment with either IL-4 or IL-13 (1-100 pM) stimulated the formation of alkaline phosphatase (ALP) dose-dependently, detected by enzyme reaction and histochemistry. IL-4 and IL-13 also induced an increase in the secretion of procollagen type I carboxypeptide (PICP) from cultured hOBs, measured by RIA. Osteocalcin secretion measured by ELISA-technique was unaffected. The rate of mineralization, assessed by von Kossa and Alizarin Red staining, was clearly enhanced in hOBs stimulated by IL-4 or IL-13. In conclusion IL-4 and IL-13 exert multiple effects on osteoblast activity in cultured hOBs. Stimulation of ALP secretion together with enhanced collagen secretion and mineralization suggests that IL-4 and IL-13 also have the capacity to maintain hOBs in a differentiated, productive phase.
Assuntos
Interleucina-13/farmacologia , Interleucina-4/farmacologia , Osteoblastos/metabolismo , Fosfatase Alcalina/metabolismo , Células Cultivadas , Humanos , Interleucina-6/biossíntese , Osteoblastos/efeitos dos fármacos , Osteocalcina/metabolismo , Fragmentos de Peptídeos/metabolismo , Pró-Colágeno/metabolismoRESUMO
BACKGROUND AND PURPOSE: Cytokines play an important role in the complex process of bone formation. We have previously found an altered skeletal phenotype with reduction of cortical bone mass in mice depleted of the 2 cytokines interleukin-4 (IL-4) and interleukin-13 (IL 13). The present study was performed to investigate a potential role of IL-4 and IL-13 in fracture healing and bone induction by demineralized xenogenic bone matrix (DXBM). METHODS: Callus formation in IL-4-(/)-IL-13-(/)- (IL-4/13 knockout) and wild-type (WT) male mice was compared using a standardized fracture model. The capacity of IL-4(-/-)IL-13(-/-) and WT male and female mice to form heterotopic bone was compared using intramuscular implants of DXBM. Bone formation and mechanical properties were evaluated by pQCT, ash weight, 3-point bending, radiology, and immunohistology. RESULTS: In the fracture investigation substantial amounts of new bone formation by 5 weeks were found, but no differences in radiographical healing, callus volume, BMD, BMC, or mechanical properties were detected between IL-4(-/-)IL-13(-/-) and WT mice. In the DXBM investigation radiographic analysis confirmed mineralization of implants in both groups, but no difference in the amount of mineral deposition (net bone formation) between IL-4(-/-)IL-13(-/-) and WT mice was found. Immunohistology showed inhibition of autonomic nerves in the capsule of the IL-4(-/-)IL-13(-/-) group along with a lack of vascularization within the implants. INTERPRETATION: Depletion of IL-4 and IL-13 does not cause any major alteration in fracture healing or heterotopic bone formation in mice. The pattern of autonomous nerve expression and expression of markers of neovascularization is, however, altered to some extent by the absence of IL-4 and IL-13.
Assuntos
Interleucina-13/fisiologia , Interleucina-4/fisiologia , Osteogênese/fisiologia , Animais , Técnica de Desmineralização Óssea , Matriz Óssea/metabolismo , Matriz Óssea/fisiologia , Remodelação Óssea/fisiologia , Calo Ósseo/fisiologia , Feminino , Consolidação da Fratura/fisiologia , Fraturas Ósseas/metabolismo , Fraturas Ósseas/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Ossificação HeterotópicaRESUMO
The aim of the present study was to study the in vivo role of IL-4 and IL-13 on bone metabolism. The skeletal phenotypes of male and female IL-13(-/-) (n = 7+7), IL-4(-/-)IL-13(-/-) (n = 7+7), and WT (n = 7+7) mice were compared. Analysis was made at 6 weeks of age (juvenile) by pQCT, and at 20 weeks of age (adult) by pQCT, biomechanical testing, and by S-IGF-1 and S-Osteocalcin measurements. The skeletal phenotype was affected only in adult male IL-4(-/-)IL-13(-/-) mice. These animals displayed a reduction in cortical bone mineral content (BMC) of both the tibia and the femur, as measured by mid-diaphyseal pQCT scans, compared with WT mice (tibia -8.2%; femur -8.5%; p < 0.01). This reduction in cortical BMC was due to a decreased cross-sectional area as a result of a reduced cortical thickness. The mechanical strength of the cortical bone, tested by three-point-bending at the mid-diaphyseal region of the femurs, demonstrated a significant reduction of displacement at failure (-11.4%), maximal load at failure (-10.6%), and total energy until failure (-29.4%). S-IGF-1 and S-Osteocalcin levels as well as trabecular bone mineral density (tvBMD) were unaffected in adult male IL-4(-/-)IL-13(-/-) mice. IL-4(-/-)IL-13(-/-) male mice show adult onset reduction of cortical bone mass and strength, indicating that the two anti-inflammatory Th(2) cytokines IL-4 and IL-13 are involved in the regulation of bone remodeling.
Assuntos
Densidade Óssea/imunologia , Reabsorção Óssea/imunologia , Reabsorção Óssea/fisiopatologia , Interleucina-13/genética , Interleucina-4/genética , Animais , Remodelação Óssea/imunologia , Reabsorção Óssea/diagnóstico por imagem , Feminino , Fêmur/diagnóstico por imagem , Fêmur/imunologia , Fêmur/fisiopatologia , Fator de Crescimento Insulin-Like I/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Transgênicos , Osteocalcina/sangue , Ovariectomia , Fenótipo , Tíbia/diagnóstico por imagem , Tíbia/imunologia , Tíbia/fisiopatologia , Tomografia Computadorizada por Raios X , Suporte de CargaRESUMO
Formation of interleukin-6 (IL-6) in osteoblasts and bone marrow stromal cells is believed to regulate osteoclast recruitment. The anti-inflammatory cytokines interleukin-4 and -13 (IL-4 and IL-13) stimulate IL-6 production in human osteoblasts. We investigated the relative potencies, and synergistic effects, between IL-4, IL-13 and interleukin-1 (IL-1) on IL-6 formation in human osteoblast-like cells. Isolated human osteoblast-like cells were incubated for 72 h in the presence of various concentrations of IL-4, IL-13 and IL-1, and IL-6 secretion was measured by ELISA. All cytokines stimulated the secretion of IL-6. The rank order of potency was IL-1>>IL-4>IL-13. There were no additive or synergistic effects between IL-4 and IL-13. However, co-stimulation with IL-1 and IL-4 resulted in a marked synergistic effect on IL-6 secretion. Co- stimulation with IL-1 and IL-13 gave a minor synergistic effect. In conclusion, IL-4/13 synergistically potentiates IL-1 induced secretion of IL-6 in human osteoblast-like cells.
Assuntos
Interleucina-13/farmacologia , Interleucina-1/farmacologia , Interleucina-4/farmacologia , Interleucina-6/metabolismo , Osteoblastos/efeitos dos fármacos , Humanos , Osteoblastos/metabolismo , Fator de Necrose Tumoral alfa/farmacologiaAssuntos
Procedimentos Cirúrgicos Ambulatórios/métodos , Discotomia/métodos , Deslocamento do Disco Intervertebral/cirurgia , Continuidade da Assistência ao Paciente , Feminino , Humanos , Tempo de Internação , Masculino , Avaliação de Resultados em Cuidados de Saúde , Medição da Dor , Satisfação do Paciente , Seleção de Pacientes , Inquéritos e QuestionáriosRESUMO
Osteoprotegerin (OPG), a member of the tumor necrosis receptor family, is produced by various tissues and inhibits osteoclast differentiation and activity. Since the metastasis of prostate cancer to bone often induces osteosclerosis, the possibility that these tumor cells secrete OPG is of interest. We have investigated whether the prostate cancer cell lines LNCaP, PC-3, and DU-145 produce and secrete OPG in vitro and if the production might be regulated by cytokines involved in remodeling of bone. OPG transcripts were detected by RT-PCR in all cell lines. OPG in culture media was analyzed by ELISA. In all three lineages, treatment with tumor necrosis factor-alpha and interleukin-1 beta dose dependently (5-5000 pM) stimulated the OPG secretion. Treatment with tumor necrosis factor-beta in increasing concentrations (1-1000 pM) stimulated OPG secretion in PC-3 but had no effect on the DU-145 and LNCaP cells. Dexamethasone (100 pM) had a small, but not significant, inhibitory effect on OPG secretion from DU-145 and LNCaP. In human non-malignant prostate cells, used as controls, there was no effect of IL-1 or TNFs on the secretion rate of OPG.
Assuntos
Citocinas/farmacologia , Dexametasona/farmacologia , Glicoproteínas/metabolismo , Interleucina-1/farmacologia , Fator de Necrose Tumoral alfa/farmacologia , Humanos , Linfotoxina-alfa/farmacologia , Masculino , Osteoprotegerina , Neoplasias da Próstata , Receptores Citoplasmáticos e Nucleares , Receptores do Fator de Necrose Tumoral/metabolismo , Células Tumorais CultivadasRESUMO
BACKGROUND: Prostasomes are small (40-500 nm), granule-like bodies, found in normal epithelial cells of the prostate and secreted into the prostate duct system. Also poorly differentiated prostate cancer cells are producing prostasomes, since we could isolate and purify prostasomes from vertebral metastases with biochemical methods. To find out whether these prostasomes are secreted into extracellular sites of the metastases, we used electron microscopy. METHODS: Small biopsies from vertebral metastases of prostate cancer, taken directly from the operating field at surgery, were immediately fixated, embedded in plastic and processed for electron microscopy. RESULTS: We found that prostasomes could be identified extracellularly in the interstitial tissues as well as in the cytoplasm of the metastatic cells. CONCLUSION: We conclude that prostasomes produced by the cells of vertebral metastases of prostate cancer are distributed both intracellularly and extracellularly in the interstitial spaces of the tissue. Thus, prostasomes of metastases could perhaps be exploited as targets for immunodiagnosis and/or immunotherapy.